PHARMADAN A/S: Financial statements 2022
CVR: 26524938
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
PHARMADAN A/S (CVR 26524938) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -3,128,264 and a net result of DKK -2,752,872 compared with DKK -2,511,252 the year before. Equity in the 2022 report amounted to DKK -4,247,190.
- Gross Profit
- DKK -3,128,264
- Profit/Loss
- DKK -2,752,872
- Equity
- DKK -4,247,190
- Total Assets
- DKK 2,682,868
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -3.1M | -2.8M | -4.2M | - |
| 2021 | - | -2.8M | -2.5M | -1.5M | - |
| 2020 | - | -8K | -1.6M | 1M | 3 |
| 2019 | - | 956K | -800K | 2.6M | 3 |
| 2018 | - | 973K | -1.6M | 3.4M | 4 |
Official annual report
Keep an eye on PHARMADAN A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout PHARMADAN A/S
PHARMADAN A/S is a Danish company of the type Aktieselskab based in Kastrup, founded in 2002. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Peter Rørvig. The board consists of Helle Rørvig, Niels Ulrik Heine and Peter Rørvig. The company is owned by H&P Rørvig Holding A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -6,382,654 and a net result of DKK -5,426,641 compared with DKK -5,113,611 the year before. Equity in the 2025 report amounted to DKK -18,955,125.